Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021 Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will...

Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada...

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla® PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...

AGRX NOTICE: Rosen Law Firm Reminds Agile Therapeutics Investors of Important Class Action Deadline – AGRX NEW YORK, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Agile Therapeutics, Inc. securities (NASDAQ:AGRX) from March 9, 2016 through...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Agile Therapeutics, Inc. – AGRX NEW YORK, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Agile Therapeutics, Inc....